2024/09/27 08:00:14 | |
---|---|
Price | |
58.90 EUR | |
Difference | 1.80% (1.04) |
ISIN | US3024913036 |
Symbol | FMC |
Exchange | Frankfurt |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 7,368 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 58.88 EUR (300) |
Ask (Ask size) | 59.22 EUR (300) |
Open | 58.90 EUR |
High | 58.90 EUR |
Low | 58.90 EUR |
Close (prev. day) | 57.86 EUR |
VWAP | 57.86 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
2024/09/27 08:00:14 | |
---|---|
Price | |
58.90 EUR | |
Difference | 1.80% (1.04) |
ISIN | US3024913036 |
Symbol | FMC |
Exchange | Frankfurt |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 7,368 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 58.88 EUR (300) |
Ask (Ask size) | 59.22 EUR (300) |
Open | 58.90 EUR |
High | 58.90 EUR |
Low | 58.90 EUR |
Close (prev. day) | 57.86 EUR |
VWAP | 57.86 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | +0.28% | -8.85% | -27.63% |
Perf (abs.) | +0.16 | -5.62 | -22.09 |
Beta | 0.74 | 0.96 | 0.76 |
Volatility | 38.06 | 46.21 | 36.52 |
Ø price 5 days | Ø volume 5 days (pcs.) | 57.19 EUR (89) |
Ø price 30 days | Ø volume 30 days (pcs.) | 57.11 EUR (62) |
Ø price 100 days | Ø volume 100 days (pcs.) | 55.34 EUR (54) |
Ø price 250 days | Ø volume 250 days (pcs.) | 54.31 EUR (59) |
YTD High | date | 62.50 EUR (2024/05/14) |
YTD Low | date | 46.76 EUR (2024/02/21) |
52 Weeks High | date | 63.80 EUR (2023/10/18) |
52 Weeks Low | date | 46.61 EUR (2023/11/10) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/09/27 | 11:29 | 58.96 EUR | 0.02 | 4 |
Stuttgart | 2024/09/27 | 08:03 | 58.96 EUR | 0.00 | 1 |
NYSE | 2024/09/26 | 22:00 | 65.97 USD | 70.84 | 19,206 |
Munich | 2024/09/27 | 08:02 | 58.92 EUR | 0.00 | 1 |
London Stock Exchange | 2024/09/05 | 11:48 | 63.07 USD | 0.15 | 1 |
Frankfurt | 2024/09/27 | 08:00 | 58.90 EUR | 0.00 | 1 |
Duesseldorf | 2024/09/27 | 09:31 | 59.12 EUR | 0.00 | 2 |
Berlin | 2024/09/27 | 08:08 | 58.96 EUR | 0.00 | 1 |
FMC CORP. |
- - |
2929 Walnut Street - 19104 Philadelphia |
Telefon: +1-215-299-6000 |
Fax: + |
E-mail: - |
FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA. |
Patricia Verduin | Member of Board of Directors |
C. Greer | Member of Board of Directors |
Carol Davidson | Member of Board of Directors |
Dirk Kempthorne | Member of Board of Directors |
Eduardo Cordeiro | Member of Board of Directors |
John Raines | Member of Board of Directors |
K'Lynne Johnson | Member of Board of Directors |
Kathy Fortmann | Member of Board of Directors |
Margareth Øvrum | Member of Board of Directors |
Robert Pallash | Member of Board of Directors |
Mark A. Douglas | Chairman of Managing Board |
Andrew D. Sandifer | Member of Executive Committee |
Diane Allemang | Member of Executive Committee |
Michael F. Reilly | Member of Executive Committee |
Ronaldo Pereira | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer